|Bid||1.5305 x 0|
|Ask||1.7720 x 0|
|Day's range||1.6490 - 1.6545|
|52-week range||1.1995 - 5.6000|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||27 Feb 2023 - 03 Mar 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Chimerix (CMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NEW YORK, November 10, 2022--Rubric Capital Management LP ("Rubric"), an investment adviser whose managed funds and accounts collectively own approximately 8.5% of the common stock of Chimerix, Inc. ("Chimerix" or the "Company") (NASDAQ: CMRX), today sent a letter to Chimerix’s Board of Directors (the "Board").
Chimerix, Vista Oil & Gas and Arcus Biosciences have been highlighted in this Screen of The Week article.